Q3 EPS Estimates for Nuvectis Pharma Increased by Analyst

Key Points

• Roth Capital raised their Q3 2025 earnings estimate for Nuvectis Pharma to ($0.21) per share, up from a previous estimate of ($0.22).
• The company recently reported a Q2 EPS of ($0.30), missing the consensus estimate of ($0.25) by $0.05.
• Insiders purchased a total of 39,045 shares worth $314,300 in the last quarter, indicating confidence in the stock's future performance.

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Equities research analysts at Roth Capital raised their Q3 2025 EPS estimates for shares of Nuvectis Pharma in a report released on Tuesday, August 12th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of ($0.21) for the quarter, up from their prior forecast of ($0.22). The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.01) per share. Roth Capital also issued estimates for Nuvectis Pharma's Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.97) EPS, FY2026 earnings at ($0.81) EPS, FY2027 earnings at ($0.80) EPS and FY2029 earnings at $3.10 EPS.

NVCT has been the topic of a number of other reports. HC Wainwright cut their price target on Nuvectis Pharma from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Monday, August 4th. Wall Street Zen lowered Nuvectis Pharma from a "hold" rating to a "sell" rating in a report on Sunday, June 29th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $15.33.

Nuvectis Pharma Stock Performance

NVCT stock traded down $0.2850 during midday trading on Thursday, hitting $6.1650. 29,083 shares of the company's stock were exchanged, compared to its average volume of 145,206. The stock's fifty day moving average price is $7.60 and its 200-day moving average price is $8.26. The company has a market cap of $156.96 million, a PE ratio of -5.28 and a beta of -0.26. Nuvectis Pharma has a one year low of $4.44 and a one year high of $11.80.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.05).

Insider Transactions at Nuvectis Pharma

In related news, major shareholder Marlio Charles Mosseri bought 5,603 shares of the company's stock in a transaction that occurred on Friday, June 20th. The shares were acquired at an average price of $7.99 per share, for a total transaction of $44,767.97. Following the completion of the acquisition, the insider owned 2,981,806 shares of the company's stock, valued at approximately $23,824,629.94. The trade was a 0.19% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders bought a total of 39,045 shares of company stock worth $314,300 in the last 90 days. Corporate insiders own 30.52% of the company's stock.

Institutional Trading of Nuvectis Pharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP increased its position in Nuvectis Pharma by 191.0% during the fourth quarter. Marshall Wace LLP now owns 124,571 shares of the company's stock worth $674,000 after buying an additional 81,757 shares during the last quarter. Northern Trust Corp increased its position in Nuvectis Pharma by 68.7% during the fourth quarter. Northern Trust Corp now owns 25,725 shares of the company's stock worth $139,000 after buying an additional 10,472 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Nuvectis Pharma during the fourth quarter worth approximately $34,000. Squarepoint Ops LLC acquired a new position in Nuvectis Pharma during the fourth quarter worth approximately $103,000. Finally, Blue Zone Wealth Advisors LLC acquired a new position in Nuvectis Pharma during the first quarter worth approximately $102,000. Institutional investors own 96.77% of the company's stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.